GSK buys respiratory drug maker Aiolos in $1.4bn deal
GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).
FTSE 100
8,089.48
09:40 23/12/24
n/a
n/a
FTSE 350
4,463.95
09:40 23/12/24
n/a
n/a
FTSE All-Share
4,421.63
09:40 23/12/24
n/a
n/a
GSK
1,324.50p
09:40 23/12/24
0.34%
4.50p
Pharmaceuticals & Biotechnology
19,938.96
09:40 23/12/24
0.90%
177.84
The deal provides GSK with access to Aiolos' AIO-001, a drug ready to enter phase II clinical development for the treatment of adult patients with asthma, with potential for additional indications including chronic rhinosinusitis with nasal polyps.
GSK will pay $1bn upfront, with an extra $400m in milestone payments if targets are met.
Founded in 2023, Aiolos Bio is a San Francisco, USA and London, UK-based clinical-stage, private, biopharmaceutical company focused on treating respiratory disease.
Reporting by Frank Prenesti for Sharecast.com